Pacira BioSciences, Inc. (PCRX)

Market Cap	1.14B
Revenue (ttm)	700.97M
Net Income (ttm)	-99.56M
Shares Out	46.28M
EPS (ttm)	-2.15
PE Ratio	n/a
Forward PE	8.69
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,333,401
Open	24.72
Previous Close	24.84
Day's Range	23.93 - 24.83
52-Week Range	11.16 - 31.67
Beta	0.86
Analysts	Buy
Price Target	30.67 (+24.88%)
Earnings Date	May 6, 2025

About PCRX

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled dos...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2011
• Employees: 790
• Stock Exchange: NASDAQ
• Ticker Symbol: PCRX
• Website: https://www.pacira.com

Analyst Forecast

According to 9 analysts, the average rating for PCRX stock is "Buy." The 12-month stock price forecast is $30.67, which is an increase of 24.88% from the latest price.

Price Target

$30.67

(24.88% upside)

Analyst Consensus: Buy